On October 3, 2023, the U.S. Food and Drug Administration (FDA) announced approval of Biogen's Byooviz (ranibizumab-nuna) as an interchangeable biosimilar to Genentech's Lucentis.
Coherent Market Insights: Global EYLEA Drug Market Size to Surpass US$ 14 30 Billion by 2030 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ CoherentMI published a report, titled, Global EYLEA Drug Market estimated value at US$ 8.79 Billion in the year 2023 and is anticipated to.
Lupin, Amman Pharma join hands to launch ophthalmic drug in West Asian market thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.
Lupin signs marketing pact with Amman Pharma for Ranibizumab biosimilar thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.